Company Overview and News
LOCAL planters with operations in Indonesia are not expected to be severely impacted by the latter’s recent decision to impose a three-year moratorium on new oil palm plantations, according to analysts.
KLKBY 2445 SMEBF 2216 4197 2291
After a long holiday break last week, the market was volatile as it sought catalysts. It started with a bearish note as global markets were bearish and ended up higher in a week after markets rebounded strongly. The FBM KLCI closed 0.3% higher at 1,803.76 points in the short trading week but the trading range was between 1,777.45 and 1,822.68 points. There was not much movement this week and yesterday, the index closed at 1,800.
1023 5225 SMEBF 4197 Q0F BSMAF 5168 IHHHF 7277 HRGHY 1818 CIMDF
KUALA LUMPUR (Sept 18): Sime Darby Property Bhd (Sime Prop) has been recognised as an index component of the Dow Jones Sustainability Indices (DJSI), after obtaining a good sustainability score that qualified it as an index constituent in the Dow Jones Sustainability Emerging Markets Index.
KUALA LUMPUR (Sept 3): The FBM KLCI is seen starting September on a cautious note and hover above the 1,790-level in line with the weaker close last Friday at most global markets on worries of extended global trade conflicts.
4502 1155 5754 MLYBY SMEBF MLYNF MIAHF 4197 3794
KUALA LUMPUR (Aug 30): Based on corporate announcements and news flow today, stocks in focus on Monday (Sept 3) may include: Malayan Banking Bhd, RHB Bank Bhd, Alliance Bank Malaysia Bhd, Media Prima Bhd, Utusan Melayu (Malaysia) Bhd, IGB Bhd, AirAsia Group Bhd, DiGi.Com, Lafarge Malaysia, Petron Malaysia Refining & Marketing Bhd and Sime Darby Bhd.
4502 1155 5227 5754 MLYBY SMEBF MLYNF MIAHF 4197 BSMAF 3794 1818
KUALA LUMPUR: The FBM KLCI ended a volatile August on a firm note, with the market seeing the re-entry of foreign funds – but still not in a big way – since the May 9 General Election. For the month, the KLCI is up 1.75% or 31.3 points to end at 1,819.66. However, the 30-stock index is still way off the all-time closing high of 1,895 on April 19. At 5pm on Thursday, the KLCI was down 0.98 of a point to 1,819.
PBLOF BRDBF 4065 7113 4197 5681 TPGVF 1295 6033 5210 TGLVY PNADF SMEBF 5819 PNAGF
KUALA LUMPUR, Aug 30 — Sime Darby Bhd said today it is expecting a slight hike in its vehicle prices after the implementation of the Sales and Service Tax (SST) starting September 1.
KUALA LUMPUR (Aug 30): Sime Darby Bhd reported a net profit of RM163 million for the fourth financial quarter ended June 30, 2018 (4QFY18) for its continuing operations, which comprises the group’s industrial, motors, logistics and healthcare businesses. This was a surge of nearly 4.8 times from RM34 million in 4QFY17.
SMEBF 4197 BSMAF 1818
KUALA LUMPUR, Aug 30 — Sime Darby Bhd posted a profit before interest and tax (PBIT) of RM1.1 billion and net earnings of RM618 million for the financial year ended 30 June, 2018 (FY2018).
KUALA LUMPUR: The FBM KLCI closed lower on Wednesday as funds took profit on Digi, Hartalega and IHH Healthcare amid a weaker broader market but stocks in focus were Bumi Armada , FGV Holdings and Supermax. At 5pm, the KLCI was down 6.26 points or 0.34% to 1,820.64. Turnover was 2.69 billion shares valued at RM2.63bil. Decliners beat advancers 629 to 355 while 337 counters were unchanged. Global stocks faltered on Wednesday as optimism over a US-Mexico trade deal faded with investors anxious about Canada’s acquiescence and eyeing a deadline for the next round of China-U.
PBLOF BRDBF 4065 4197 5681 1295 6033 5210 PNADF 5225 SMEBF 5819 Q0F IHHHF PNAGF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...